A future where no child dies of neuroblastoma or suffers due to the treatment they receive
Help us make this change
How you can helpResearch. Support. Awareness.
We are striving for better outcomes for children and families affected by childhood cancer. Solving Kids' Cancer UK has a particular focus and expertise in the rare and complex cancer, neuroblastoma. We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatments they need as close to home as possible.
Research
We initiate and fund pioneering and best-in-class clinical research to save lives and improve outcomes for children.
Support
We provide a family support service, led by professionals with personal experience of caring for a child with neuroblastoma.
Awareness
We raise awareness of childhood cancer and advocate and campaign for positive change.
The need for our research
Clinical research brings the all-important hope that families need when facing a childhood cancer diagnosis. We are working towards a future with much-needed improved outcomes for children with neuroblastoma.
100
children in the UK are diagnosed with neuroblastoma every year.
50%
survival rate for children diagnosed with high-risk neuroblastoma.
10%
survival rate for children with high-risk neuroblastoma who relapse.
Christmas Concert
Join us this December in London for this wonderfully festive and special event
Kids Get Cancer Too
Read our brand-new manifesto, calling on the next Government to bring in kinder, more effective childhood cancer treatments.
BBC Radio 4 Appeal
Actress Natalie Cassidy presented our BBC Radio 4 Appeal this September.
Our latest news
AMXT1501/DFMO (polyamine inhibition) therapy
AMXT1501/DFMO (polyamine inhibition) therapy
New decision-making tool for treatment of relapsed and refractory neuroblastoma launched
A brand new support tool developed by Advanced Nurse Practitioner Helen Pearson is now available to parents facing difficult decisions in their child's treatment and care.
Funding award extends clinical trial for children with relapsed or refractory neuroblastoma
We're pleased to announce the extension of funding for the MiNivAn trial, investigating new combination therapies for children with relapsed or refractory high-risk neuroblastoma.